Navigation Links
Inovio Pharmaceuticals to Present at BioCentury's "Future Leaders in the Biotech Industry" Conference
Date:3/28/2013

release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or dev
'/>"/>
SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
2. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
3. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
4. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
5. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Inovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
7. Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
8. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
9. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
10. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
11. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... an intimidating job description: ensure products meet quality standards ... tight budgets and escalating regulations, quality leaders also have ... costs and risk. Those who don,t effectively ... quality function as well as marketplace failure and regulatory ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Week in Review: The Latest from PhRMA 2
... 17 Regado Biosciences, a privately held company leading the ... David J. Mazzo , PhD, President and CEO, will be presenting ... in Boston, Massachusetts . Dr. Mazzo,s presentation will be given ... in the Robinson Room and will include an overview of ...
... June 17 Salvin Dental Specialties, Inc. and LifeNet Health ... advance LifeNet Health,s OraGraft™ allograft products in the dental market. , ... The two companies ... the existing relationship between these two companies, which provides LifeNet Health ...
Cached Medicine Technology:Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 2Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 3LifeNet Health and Salvin Dental Specialties Announce Partnership 2LifeNet Health and Salvin Dental Specialties Announce Partnership 3
(Date:3/29/2015)... (PRWEB) March 30, 2015 Over 50 ... symptoms tied to undiagnosed autoimmune, thyroid, or hormone disorders. ... disorders, has personally treated hundreds of patients dealing with ... unaware of the treatment options for their ailments. Her ... solutions to women living with fatigue, brain fog, and ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 Adults ... that agencies promote nationally on the web can now ... permanent life insurance quotes can now be explored while ... http://quotespros.com/life-insurance.html . , Learning the differences between what a ... can be a challenge for some men and women. ...
(Date:3/29/2015)... March 29, 2015 The Contract ... trials and research, manage data results and help ... clients reach regulation standards. Contract research organizations (CROs) ... device manufacturing sectors. Industry operators provide clients with ... late-stage clinical research for Food and Drug Administration ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 Final ... new transition from Pixel Film Studios, entitled TranSports. ... made exclusively for Final Cut Pro X,” said Christiana ... users the tools needed to effortlessly transition using this ... TranSports, a new and uniquely styled transition pack for ...
(Date:3/28/2015)... Coffee could not only perk you up in ... disease, researchers have found. , They found that those who ... antioxidants. Antioxidants fight gum disease. Does coffee, then, help fight ... Henry M. Goldman School of Dental Medicine explored in a ... the Journal of Periodontology. , “This is the first long-term ...
Breaking Medicine News(10 mins):Health News:How to Turn Mid-life into the Good Life 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2
... new surgical approach to metabolic disease, may provide ... This data was presented today at the ... Meeting & Clinical Congress.(Logo: ... surgery," Chief of Gastrointestinal Metabolic Surgery at Weill ...
... China, the Netherlands Organization for Scientific Research and the ... with their Chinese counterparts regarding the theme for the ... round, the partners have selected the theme of "integrated ... level rise." , NWO and KNAW formulated the ...
... SAN DIEGO, May 14 Amylin Pharmaceuticals, Inc. (Nasdaq: ... in response to Carl Icahn:"Icahn Associates has been criticizing ... only fair to point out, according to Icahn,s own ... , "Icahn,s own performance elsewhere is well documented." About ...
... 14 John Hancock Long-Term Care (LTC) Insurance has ... services with more than 15 years of experience, to ... programs for its policyholders and their families. Beginning May ... as part of John Hancock,s individual and group LTC ...
... Conjugate Technology Used in Cimzia(R) Through Exclusive Nektar-UCB ... (Nasdaq: NKTR ) confirmed today UCB,s ... (FDA) has approved Cimzia(R) (certolizumab pegol), the only ... treatment of adult patients with moderately to severely ...
... Inc. (Nasdaq: TSTF ) , ... services, today announced that its travel nurse and allied ... agreement giving it the opportunity to provide temporary healthcare ... networks devoted exclusively to cancer treatment and research. ...
Cached Medicine News:Health News:Can New Surgery Revolutionize Diabetes Treatment? 2Health News:Can New Surgery Revolutionize Diabetes Treatment? 3Health News:China and the Netherlands join forces for research into water management 2Health News:Amylin Issues Statement Regarding Open Letter From Icahn 2Health News:John Hancock Selects CHCS Services to Manage Long-Term Care Insurance Provider Discount and Caregiver Programs 2Health News:John Hancock Selects CHCS Services to Manage Long-Term Care Insurance Provider Discount and Caregiver Programs 3Health News:John Hancock Selects CHCS Services to Manage Long-Term Care Insurance Provider Discount and Caregiver Programs 4Health News:Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 2Health News:Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 3Health News:TeamStaff Rx Signs Staffing Agreement With One of the Nation's Largest Healthcare Services Networks 2Health News:TeamStaff Rx Signs Staffing Agreement With One of the Nation's Largest Healthcare Services Networks 3
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
Medicine Products: